Our Science
CAR T-cell therapy is revolutionary technology where patients’ own immune cells, called T-cells, are reprogrammed to recognise and destroy cancer cells. This has proven to be a powerful therapy for refractory blood cancers but to date has lacked efficacy for the treatment of solid cancers. Leucid’s Lateral CAR platform builds upon second-generation CAR-T model which develops CAR molecules designed to adopt a more natural biological configuration within the T-cells. Our technology gives properties to CAR-T cells enabling them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies, enhancing T-cell potency and generating a persistent long-term response with the potential for reduced toxicity.
What is CAR T-cell therapy?
CAR T-cell therapy is a pioneering technology involving the reprogramming of patients’ own immune cells (T-cells). As cancer cells have evolved from a patient’s own healthy cells they are able to hide from their immune system. Modifying immune cells with Chimeric Antigen Receptors (CARs) enables the immune cells to recognise and destroy the cancer cells.
​
CARs contain an antigen binding domain for recognition of tumour cell targets, and a signalling domain, which instructs the cells to attack. Expression of a CAR in a type of an immune cell, called a T cell, produces CAR T-cells which thereby acquire the ability to find and destroy cancer cells.
​
To produce a CAR T-cell product, a blood sample is collected. In the lab the immune cells are extracted and genetically engineered to express the CAR construct. The resulting CAR T-cells are now equipped to recognise and attack cancer cells. The CAR T-cells are expanded in the lab until there is a sufficient dose, before being infused back into the patient’s blood stream. The CAR T-cells travel around the blood until they meet tumour cells which they are now able to eliminate.
.png)
Treating solid tumours with CAR T-cells
Solid tumours represent 90% of cancers and are fast becoming the leading cause of death in the Western world. It is evident that there is a clear unmet need for more effective treatments for these cancers. CAR T-cell therapy has proven to be a powerful therapy for refractory blood cancers, however, the most common cause of cancer deaths worldwide are solid tumours, for which CAR T-cell therapy currently has little clinical benefit. Progress within the solid tumour field has been hampered due to the multiple defence mechanisms employed by the tumour cells, thus insulating them both from conventional treatments and from gene and cell therapies.
Our approach
At Leucid Bio we are developing improved lateral CAR-T therapies as well as cell engineering technologies that produce better and more durable responses than second-generation CAR-Ts. Our dedicated team of researchers use an integrated approach to overcome key challenges in CAR-T cell treatment of solid tumours, aiming to realise the full potential of this cutting-edge therapy for patients.
​
​
Our Technologies
Leucid's integrated approach brings together a novel lateral CAR T platform and additional CAR T cell 'armour' to overcome key challenges in CAR T cell treatment of solid and blood tumours, including:
​
-
Lack of suitable targets: A suitable target must be chosen for CAR T-cells to recognise and attack tumour cells. Unfortunately, solid tumours share many surface proteins with healthy cells. We are working with a highly specific yet extensive set of targets which recognise 80% of cancers with minimal toxicity.
-
Tumour microenvironment: The hostile, immunosuppressive tumour microenvironment makes it difficult for immune cells to thrive and survive to successfully destroy tumours. Our parallel CAR technology overcomes this with improved potency and serial killing.
-
Poor trafficking and tumour infiltration: CAR T-cells must be able to find the tumour and must survive long enough to reach it and attack the cancer cells. Our lateral CAR technology improves CAR T-cell persistence so they can survive in the blood for longer periods of time. Additional ‘armour’ directs our CAR T-cells specifically to the tumour site.
​
Lateral CAR platform
Previous generations of CAR-T cell therapies built on the original concept of linear fusion:
​
-
First generation CAR-T therapies consist of an activating motif such as CD3ζ alone joined to a single targeting domain​
-
Second generation CAR-T therapies consist of CD3ζ fused to one costimulatory domain and a single targeting domain​
-
Third generation CAR-T therapies consist of CD3ζ fused with two costimulatory domains and a single targeting domain ​
-
The clinical success of CAR T-cell therapy against haematological cancers has largely resulted from the transition from the original first generation CARs to second generation CARs. However, despite the success of second generation CAR T-cells, only marginal improvement in T cell activity was seen with third generation CAR T-cells, highlighting the sub-optimal nature of the linear arrangement. ​
-
Leucid Bio’s lead asset is based on a novel lateral CAR structure, in which complementary signalling domains are integrated in parallel across the cell membrane. This formation replicates the natural side-by-side position of these molecules across the cell membrane that is seen in endogenous immune receptors, achieving enhanced tumour targeting, selectivity and engagement in multiple targets on the tumour cell surface. The Lateral CAR Platform provides better durability and functional persistence to deliver a step change in therapeutic approach, safety, and efficacy. The technology enables CAR-Ts to consistently outperform previous generations of CAR T-cells in pre-clinical studies, enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.
​
.png)
LEU011 - NKG2D CAR T-cell therapy
Leucid Bio’s lead asset LEU011 is a lateral CAR-T targeting NKG2D stress ligands. The NKG2D receptor is an activating immune receptor that triggers cell death upon recognition of one or more of the eight human NKG2D ligands expressed on transformed, infected or damaged cells. NKG2D ligands are expressed on more than 80% of human tumour cells, positioning LEU011 as a novel CAR-T for the potential treatment of multiple cancers. To date, LEU011 has demonstrated significant anti-tumour activity in preclinical solid tumour models.
In first quarter 2025, the Company initiated the dose-escalation Phase 1 AERIAL trial evaluating LEU011 for treatment of refractory solid tumours.